Complete Response Letter Issued for Remoxy

AUSTIN, Texas, Aug. 06, 2018 (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc. (Nasdaq: PTIE) today announced it had received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA) for Remoxy,...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news